Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC)

Otolaryngology - Head and Neck Surgery

Volumn 137, Issue 5, 2007, Pages 722-728

  Provenzano, Matthew J ^a   Fitzgerald, Matthew P ^a   Krager, Kimberly ^a   Domann, Frederick E ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BUTYRIC ACID; HISTONE; IODINE 125; MESSENGER RNA; SODIUM IODIDE SYMPORTER;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CONTROLLED STUDY; CULTURE MEDIUM; DNA METHYLATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN TISSUE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CARCINOMA;

ACETYLATION; AZACITIDINE; BLOTTING, WESTERN; BUTYRATES; CELL LINE, TUMOR; DNA METHYLATION; DRUG THERAPY, COMBINATION; EPIGENESIS, GENETIC; HUMANS; IODINE RADIOISOTOPES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SODIUM IODIDE; SYMPORTERS; THYROID NEOPLASMS;

EID: 35448983934     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2007.07.030     Document Type: Article

References (25)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Patel A., Jhiang S., Dogra S., et al. Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents. Pediatr Res 52 (2002) 737-744
3. Ward L.S., Santarosa P.L., Granja F., et al. Low expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Lett 200 (2003) 85-91
4. Castro M.R., Bergert E.R., Goellner J.R., et al. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 86 (2001) 5627-5632
5. Caillou B., Troalen F., Baudin E., et al. Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 83 (1998) 4102-4106
6. Gaut A.W., Niu G., Krager K.J., et al. Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS). Head Neck 26 (2004) 265-271
7. Furuya F., Shimura H., Suzuki H., et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145 (2004) 2865-2875
8. Puppin C., D'Aurizio F., D'Elia A.V., et al. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 146 (2005) 3967-3974
9. Kitazono M., Robey R., Zhan Z., et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86 (2001) 3430-3435
10. Venkataraman G.M., Yatin M., Marcinek R., et al. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 84 (1999) 2449-2457
11. Dohan O., De la Vieja A., Paroder V., et al. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24 (2003) 48-77
12. Liang J.A., Chen C.P., Huang S.J., et al. A novel loss-of-function deletion in sodium/iodide symporter gene in follicular thyroid adenoma. Cancer Lett 230 (2005) 65-71
13. Santos-Rosa H., and Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 41 (2005) 2381-2402
14. Neumann S., Schuchardt K., Reske A., et al. Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules. Thyroid 14 (2004) 99-111
15. Kelly W.K., O'Connor O.A., Krug L.M., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 (2005) 3923-3931
16. Momparler R.L. Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol 32 (2005) 443-451
17. Chuang J.C., Yoo C.B., Kwan J.M., et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol Cancer Ther 4 (2005) 1515-1520
18. Li W., Venkataraman G.M., and Ain K.B. Protein synthesis inhibitors, in synergy with 5-azacytidine, restore sodium/iodide symporter gene expression in human thyroid adenoma cell line, KAK-1, suggesting trans-active transcriptional repressor. J Clin Endocrinol Metab 92 (2007) 1080-1087
19. Issa J.P., Gharibyan V., Cortes J., et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23 (2005) 3948-3956
20. Dobosy J.R., and Selker E.U. Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci 58 (2001) 721-727
21. Fuks F., Hurd P.J., Wolf D., et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 278 (2003) 4035-4040
22. Fuks F., Hurd P.J., Deplus R., et al. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 31 (2003) 2305-2312
23. Mutskov V., and Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. Embo J 23 (2004) 138-149
24. Jeong H., Kim Y.R., Kim K.N., et al. Effect of all-transretinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol 33 (2006) 875-882
25. Kogai T., Curcio F., Hyman S., et al. Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J Endocrinol 167 (2000) 125-135